What drugs are contained in Duzallo?
Duzallo contains allopurinol and lesinurad. Duzallo is once-daily, oral xanthine oxidase inhibitor (allopurinol) and URAT1 inhibitor (lesinurad).
Duzallo is used in patients with gout who have not achieved target serum uric acid (sUA) levels with allopurinol alone. This fixed-dose combination addresses both of the fundamental causes of hyperuricemia – overproduction and underexcretion of serum uric acid.
On April 15, 2019, the FDA announced the discontinuation of Duzallo (allopurinol and lesinurad). The discontinuation was due to business reasons, and not due to any safety, efficacy or quality issues.
Duzallo is discontinued effective February 1, 2019.
Drug information
- Duzallo Information for Consumers
- Duzallo prescribing info & package insert (for Health Professionals)
- Side Effects of Duzallo (detailed)
